Skip to main content

Available now: Cannabis Professional, the authoritative e-mail newsletter tailored specifically for professionals in the rapidly evolving cannabis industry. Subscribe now.

Part of cannabis and investing

Cannabis sector valuations continue to climb new heights, raising fresh concerns that a pullback is overdue and some investors could get dinged.

The marijuana industry was trading at 41.1 times projected 2019 earnings before interest, taxes, depreciation and amortization (EBITDA) as of Friday, according to Echelon Wealth Partners. That is the highest valuation on record, in weekly data that go back to January of 2017. Pot stocks have been riding a multi-week rally, sparked when U.S. alcohol giant Constellation Brands Inc. made a multibillion-dollar investment in Canopy Growth Corp., along with rumours of other deal-making.

Story continues below advertisement



In its report, Echelon also looked at valuations for “comparable” non-cannabis companies – including alcohol and tobacco firms, which are sometimes referred to as “sin stocks.” No surprise, cannabis valuations are considerably more stretched.



One takeaway: It’s generally cheaper to invest in non-cannabis companies that have, or are looking to get, a taste of the marijuana sector. For instance, Canopy Growth is trading at 178 times projected 2019 EBITDA as of Friday. But Constellation Brands, which will have a near-40-per-cent stake in Canopy after approvals, is trading at 15.7 times projected earnings.

That’s also the case with Molson Coors Brewing Co. and Hydropothecary, recently rebranded as Hexo Corp. Molson Coors Canada announced in August it was partnering with the Quebec-based producer on a new joint venture to develop non-alcoholic, cannabis-infused beverages. As part of the deal, Hexo issued warrants to Molson to buy shares in the cannabis producer. Molson Coors is trading at 9.6 times projected 2019 EBITDA, compared with 28.8 for Hexo.



Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Discussion loading ...

Cannabis pro newsletter